ARCHIVES

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

FDA, NCI Near Agreement On Handling INDs

January 28, 1977

In Brief: Simone Named New Director At St. Jude; Schein To Leave Georgetown For Job At Smith-Kline

September 16, 1983

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

April 17, 1987

In Brief: House Appropriations Subcommitee Plans Hearing On NCI March 24; New DTP Director Sought

February 25, 1983

As Sequestration Hits: Varmus on Living in “Pretty Awful Times”

June 26, 2013

NCAB Calls For Modification Of Rules For NIH Scientist-Industry Collaboration

December 10, 2010